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Different animal models for peritoneal dialysis (PD) have been used in the past decades to develop PD fluids compatible with
patient life and to identify markers of peritoneal fibrosis and inflammation. Only few of those studies have taken into account
the importance of uraemia-induced alterations at both systemic and peritoneal levels. Moreover, some animal studies which have
reported about PD in a uremic setting did not always entirely succeed in terms of uraemia establishment and animal survival. In
the present study we induced uraemia in the recently established mouse PD exposure model in order to obtain a more clinically
relevant mouse model for kidney patients. This new designed model reflected both the slight thickening of peritoneal membrane
induced by uraemia and the significant extracellular matrix deposition due to daily PD fluid instillation. In addition the model
offers the opportunity to perform long-term exposure to PD fluids, as it is observed in the clinical setting, and gives the advantage
to knock out candidate markers for driving peritoneal inflammatory mechanisms.
1. Introduction
End Stage Renal Disease (ESRD) affects more than 200,000
people in Europe per year and 20,000 of those are peritoneal
dialysis (PD) patients. This number is higher in the rest of
the world and although in Europe patients undergoing PD
are still less than the inmates on hospital-based haemodialysis
(HD), this number is expected to increase over the time since
PD succeeds over HD in terms of quality of life [1] and cost
effectiveness [2, 3]. Moreover, much research on PD has been
carried out to improve patient survival and thus qualifies a
good alternative for HD treated patients.
Uraemia is represented by accumulation in the body
of urea and other organic waste products of metabolism
normally filtered out by the kidneys. It can only be treated
by replacing kidney function that nowadays, due to the
insufficient number of kidneys available worldwide for trans-
plantation, occurs mainly by dialysis.
In the last decade different animal models for PD fluid
exposure have been designed and have been mainly per-
formed in rat [4, 5]. The combining effort of our present
groups to study the effect of additions in the rat PD expo-
sure model [6, 7] resulted also in the development of the
first established mouse PD exposure model published by
Gonza´lez-Mateo et al. [8]. PD rodent models have been used
to introduce in the market PD fluids more compatible with
the patient life and have offered opportunities to study PD
fluid additions. Moreover those models allowed identify-
ing important biomarkers driving peritoneal inflammatory
mechanisms that occur during long-term exposure to PD
fluids and, as amatter of fact, the failure of the technique itself.
Only few animal studies reported PD in a uremic setting,
which is most likely caused by the difficult and delicate
procedure needed to induce uraemia, resulting in a low
success rate of this technique.
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Figure 1: Experimental design. 5/6 nephrectomy was executed at day 1. After a resting period of 10 days a customer made catheter was
implanted under the skin at the back side with the tip positioned within the peritoneal membrane. Daily PD fluid instillation was performed
from day 16 to day 70 when the mice were sacrificed; PET test and tissue sampling were carried out. Blood withdrawal was performed at days
0, 15, and 70 in order to verify uraemia establishment.
In the present study we wanted to get close to the PD
patient clinical condition by combining a long-term exposure
model of PD in mouse with uraemia, sine qua non condition
for a patient to start PD treatment or a renal replacement
therapy in general.
2. Methods
2.1. Animals and Experimental Design. The study was per-
formed on 30 female C57BL/6 mice (Harlan CPB, Horst,
Netherlands) aged 12–14 weeks, weighing approximately 20 g
at the start of the study. Animals were randomly assigned
to the following groups: 10 uremic mice undergoing 5/6
nephrectomy (5/6 NX), 10 uremic PD mice undergoing 5/6
nephrectomy and catheter implantation and exposed to PD
fluid (5/6 NX + PD), and 10 healthy controls (control). Mice
were housed under standard conditions and were given food
and water ad libitum. Health conditions were checked daily.
Mice were weighed daily after surgery during a period of
10 days and weekly for the remainder of the experiment.
Animals that lost more than 20% of their body weight or
showed abnormal activity were excluded from the experi-
ment.The experimental protocolwas approved by theAnimal
Welfare Committee at the VU University Medical Center,
Amsterdam. Experimental design is shown in Figure 1.
2.2. 5/6 Nephrectomy. In order to make mice uremic, 5/6
nephrectomy was performed under isoflurane anaesthesia
(4% for induction, 2-3% for maintenance). 0.05–0.1mg/kg of
buprenorphine (Temgesic) was injected intramuscularly 15–
30minutes preoperatively.The animal was shaved around the
abdominal region and was placed on a heating pad. A ventral
midline incision was made through the skin followed by an
incision along the linea alba.Through the laparotomy the left
kidney was released from its capsule by using surgical forceps
and wet cotton swabs. At this point the kidney could be
easily positioned on top of the peritoneum and was placed on
awound pad.The anterior and posterior 1/3 part of the kidney
were impaired by using a monopolar electric blade. The
remaining functional 1/3 of the left kidney was placed back
into its original position in the abdominal cavity. Following
the same procedure, also the right kidney was removed from
the abdominal cavity and released from the capsule. A total
ligation with insoluble suture was applied, which included
the kidney vein, artery, and urethra. After ligation, the right
kidney was completely removed.This procedure resulted in a
reduced kidney function by 5/6th of its original function.The
main steps of the procedure are shown in Figure 2.
2.3. Catheter Implantation. Customized mouse catheter
(MMP-4S-061108A, Access Technologies, Ridgeway, USA)
was implanted at day 10 under isoflurane anaesthesia (4% for
induction, 2-3% formaintenance). An incision in the skinwas
made, skin was separated frommuscle layer, and a small hole
was made in the lateral side of the abdomen by means of a
needle. The catheter was implanted under the skin with the
mouse-o-port positioned subcutaneously at the back-right
side and the tip within the peritoneal cavity through the
hole previously made. The whole procedure is described by
Gonza´lez-Mateo et al. [8].
2.4. Peritoneal Exposure Model. Instillation of 2mL of peri-
toneal dialysis fluid (PDF) (Dianeal 3, 86%, Baxter, USA) was
performed daily during a period of 8 weeks via the previously
implanted mouse-o-port connected to the peritoneal cavity
via the catheter. First injection was conducted after a resting
period of 7 days from surgery to allow the operational
wound’s healing process around the catheter and avoid
leakage of fluid outside the peritoneal cavity.
2.5. Serum Analysis. 200𝜇L of blood was drawn via facial
vein puncture at days 0 and 15 (resp., before the nephrectomy
and the first injection of PD fluid) and at day 70 (end point).
BioMed Research International 3
(a) (b) (c)
(d) (e) (f)
Figure 2: 5/6 nephrectomy: surgical procedure. (a) Through the laparotomy the left kidney was released from its capsule by using surgical
forceps and wet cotton swabs. (b) Left kidney was released from the capsule. (c) A monopolar electric blade was used to impair the anterior
and posterior 1/3 part of the kidney. (d) A total ligation with insoluble suture was applied, which included the kidney vein, artery, and urethra.
(e) Right kidney was totally removed from the body. (f) Both muscle layer and skin were closed by continuous sutures.
At all the time points, serum samples were analysed for
urea and creatinine levels. For determination of urea levels
a kinetic test with urease and glutamate dehydrogenase was
used. Creatinine levels were detected by indirect immunoflu-
orescence assay. Measurements were performed by using
spectrophotometer Cobas8000 (c702), Roche Diagnostics.
2.6. Immunostaining for Peritoneal Thickness. Parietal peri-
toneal biopsies were collected from the opposite side from the
catheter installation. Biopsies were fixed in Bouin’s solution,
embedded in paraffin, cut into 5𝜇m sections, and stained
withMasson’s trichrome. Peritonealmembrane thickness was
determined using light microscopy (Leica CTR6000, with
Leica Microsystems LAS-AF6000). Photographs were made
usingOlympus BX41 clinical microscope andOlympus DP20
digital camera using cell acquisition software. Peritoneal
thickness of each animal was calculated by the median of
measurement taken every 50𝜇m from one side to the other
of the tissue sample.
2.7. Statistical Analysis. Data were analysed using GraphPad
Prism software (La Jolla, CA). Statistical analysis was per-
formed using one-way ANOVA test to compare the groups.
A 𝑃 value < 0.05 was considered statistically significant. Urea
and creatinine data were shown as means ± SD. Thickness is
represented in boxplots.
3. Results
In order to mimic in mice the clinical situations of peritoneal
dialysis patients, uraemia was induced by performing 5/6
nephrectomy. This 5/6 nephrectomy surgery resulted in
a functional kidney capacity 1/6th of the original kidney
volume. 15 days after surgery a significant increase of serum
urea levels was already seen (data not shown), which was
maintained throughout the study period. At the end of the
study the nephrectomized mice showed an almost twofold
increase in both urea (15 ± 2.71 versus 8.32 ± 2.38; 𝑃 < 0.01)
and creatinine serum levels (70.80 ± 40.00 versus 33.50 ±
6.95) when compared to the healthy control group (Figures
3(a) and 3(b)), indicative for a uremic status. Throughout
the experiment nephrectomized mice were in good health
as indicated by increasing body weight during the study
period, which was comparable between all three groups. As
expected, all nephrectomized mice showed a drop in body
weight within the first week after surgery but recovered the
following week (Figure 3(c)).
The PDF-treated group showed a significant increase in
peritoneal thickness compared to both the 5/6 NX and the
control groups (Figure 4; 41.14 ± 5.04 versus 26.71 ± 3.59
versus 13.00 ± 3.16; 𝑃 < 0.001). This demonstrates that
chronic instillation of PDF in our mouse model caused peri-
toneal thickening and inflammation of the submesothelial
compact zone comparablewith the clinic situation of a patient
4 BioMed Research International


































































0 7 14 21 28 35 42 49 56 63 70
Control
5/6 NX 
5/6 NX + PD
(c) Body weight
Figure 3: (a and b) Blood chemistries at days 0 and 70, respectively, before and after induction of uraemia with 5/6 nephrectomy. (a) Serum
levels of creatinine. Time 0: 37.20 ± 19.16 5/6 NX versus 39.00 ± 0.82 control; time 70: 70.80 ± 40.00 5/6 NX versus 33.50 ± 6.95 control.
(b) Serum levels of urea: white bars indicate healthy controls; black bars indicate mice undergoing 5/6 nephrectomy. 𝑃 values ∗∗ < 0.01,
∗ ∗ ∗ < 0.001. (c) Mean increases in body weight during uraemia induction. Values are expressed as percent of starting body weight. Black
line indicates healthy controls, blue line indicates uremic group, and red line indicates uremic group undergoing PD.
undergoing PD. Moreover, the peritoneal thickening already
found in the nephrectomized group showed that uraemia
cannot be omitted in a model of PD.
4. Discussion
Uraemia is the terminal clinical manifestation of kidney
failure and it represents the main reason for a patient to
be introduced to a dialysis treatment. Systemic changes that
occur in uremic patients such as the significant increase
in advanced glycation end products (AGEs), nitric oxide
synthase (NOS), Tumor Necrosis Factor Alpha (TNF𝛼), and
Vascular Endothelial Growth Factor (VEGF) levels, but also
hyperosmolarity and blood pressure itself, may influence
peritoneal permeability and cause thickening of the extracel-
lular matrix and mild vasculopathy [9, 10]. These alterations
induce peritoneal damage and may therefore complicate the
PD procedure in patients.
Peritoneal damage in PD patients mainly depends on the
balance between chronic damage caused by bioincompati-
bility of the PD fluids currently available in the market and
repair mechanisms. Over the years different animal models
of PD have been used to research into the use of different
peritoneal dialysis fluids [11–14] and addition of substances
to the dialysis fluid and treatment [6, 15].
Animal studies have shown an independent contribution
of uraemia to modulating inflammatory events that alter the
function of the peritoneal membrane although these events
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Figure 4: Effect of uraemia and PD fluid exposure on the parietal peritoneal thickness. (a–d) Masson’s trichrome staining of parietal
peritoneum showed a slight and a high increase of extracellular matrix deposition inmice undergoing 5/6 nephrectomy, respectively, exposed
(c) or not (b) to standard PD fluid. Magnification ×20. (Control: 13.00 ± 3.16; 5/6 NX: 26.71 ± 3.59; 5/6 NX + PD: 41.14 ± 5.04.) 𝑃 values
∗ ∗ ∗ < 0.001.
are often obscured by the effects of PD fluid induced injury
[11]. Nevertheless, in anephric rats undergoing continuous
ambulatory peritoneal dialysis (CAPD) uraemiamodifies the
permeability of peritoneum to both water and solutes [16].
In rat models exposed to PD fluid uraemia contributed to
ultrafiltration failure, leading to angiogenesis and causing an
increment in omental mast cells number [13].
Uraemia-induced alterations at both systemic and peri-
toneal level should not be underestimated and experimental
animal models of renal disease should take into account
the important effect of uraemia. Although the study of the
peritoneal membrane alterations promoted by the PD fluids
alone, avoiding the effect of other variables, is a very helpful
model, it could be very interesting for several approaches to
analyse the combined effect of PD exposure and uraemia.
Despite that, only few studies report on PD in uremic
animals. The procedure to obtain uraemia in animals indeed
is not so easy and many models still show high percentage of
drop-out and low rate of success especially when combined
with long-term exposure to PD fluids. In rabbit models
partial nephrectomy (total removal of one kidney and 5/6
nephrectomy of the other one) has been performed but
only moderate uraemia has been reached [17]. More studies
have been performed on rats: bilateral nephrectomy caused
acute uraemia and, on the other hand, the removal of only
one kidney did not induce significant changes in urea and
creatinine blood levels. Moreover, animals were experiencing
diarrhea and loss of appetite and body weight [16].
Our group also had previously developed a uremic rat
PD model consisting of total removal of the left kidney and
double artery ligation of the right one (5/6 nephrectomy).
In this model both urea and creatinine serum levels were
shown to be threefold increased after only three weeks
from the nephrectomy and kept stable during five weeks of
exposure to PD fluid (Ferrantelli et al., pending revision).
Although this model allowed us to obtain important striking
results regarding the protective effect of some additive to
the PD fluid, the percentage of drop-out was still too high.
Unfortunately, 5/6 nephrectomy itself in rats caused 20% of
drop-out, with even higher drop-out when technical failure
due to omentum wrapping of the catheter during the PD
treatment was taken into account.
In this study we present a novel animal model where both
uraemia and daily PD treatment were combined inmouse. As
a consequence of the 5/6 nephrectomy only 1/6th of the total
kidney volume is preserved and remains functional during
the whole period of daily peritoneal fluid administration.
This model fulfils the need to reduce the percentage of
drop-out due to both nephrectomy and PD treatment. Drop-
out caused by 5/6 nephrectomy was decreased from 20% in
the rat model to less than 5% in the mouse model. Moreover,
this model circumvents PD treatment-related loss of animals
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such as omentum overgrowth and wrapping of the catheter
(drop-out due to catheter obstruction is about 50% in the rat
model) [5].
Taken together, this new technique reduces the number
of animals needed for research and enables extending time
of exposure to PDFs. Indeed, daily treatment of this mouse
model with PDF for 8 weeks was well tolerated and might be
extended for a longer period. Our consideration is based on
the evidences that the animals were healthy during and till
the end of the experiment (no evidences of discomfort and
no loss of body weight or decrease of appetite) and the serum
levels of both creatinine and urea were twofold increased
compared to the controls but still within acceptable levels.
The PD mouse model represents a gold standard pro-
cedure [8] and many experiments based on it have been
performed in the last years in order to study Epithelial-
to-Mesenchymal Transition (EMT) and the involvement of
Th17 cells in fibroticmechanisms occurring during long-term
exposure to PDF [18, 19].
In our study we wanted to propose the PD mouse model
within a uremic setting in order to mimic as closely as
possible the situation in a patient with chronic kidney failure
undergoing PD. In addition our mouse model will give the
advantage to knock out genes playing a crucial role in the
peritoneal inflammatory mechanism that occurs during PD
and will open opportunities to study pathways involved in
fibrosis, since much more reagents are available in mice.
5. Conclusions
Besides the PD-related effects on fibrosis in mice, we showed
that uraemia also affects this phenomenon, which is in
accordance with patient studies.
To mimic this clinical setting, we developed a mouse
model with important features observed in renal failure
patients. Indeed this newmouse model gives the opportunity
to study PD in concomitance with peritoneal and systemic
changes caused by uraemia, often not taken into account in
animal studies. Importantly, long-term in vivo experiments
can be performed in this model, eventually resulting in
less harmful effects of biocompatible PDFs as well as PDFs
supplemented with protective additives, both favorable for
patients.
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